United States: A new treatment made from a modified darobactin compound has shown promise in fighting tough bacterial infections in animals. This could help against harmful bacteria which already resembles to E. coli, which are becoming harder to treat with current antibiotics. As bacteria grow resistant to medicines, finding new treatments is more important than ever.
Scientists writing for ACS Infectious Diseases have synthesized a new form of darobactin which was originally isolated from bacteria and could become a new antibacterial agent. Even within the ineffective compound, the researchers prove its efficiency against drug-resistant bacteria such as E. coli when tried in animal test.
As this information is reported by the Scitechdaily.com, this particular research was published at a time that the WHO marked the World Antimicrobial Resistance Awareness Week, from November 18 to 24.
The Problem of Antibiotic Resistance
In early 2024 the World Health Organization expanded its list of bacterial pathogens that can develop antibiotic resistance to include:
Acinetobacter baumannii, Pseudomonas aeruginosa and E.coli amongst others. Despite the call for new antibiotics that can target these priority bugs, the researchers do not have too many weapons.
The first one, that could be used to break resistance was named darobactin, which is antibiotic produced by bacterium. Darobactin interferes with an important protein requisite in the various bacteria cell, which leads to their destruction.
Before that, while working with Rolf Müller, Jennifer Herrmann and colleagues determined that darobactin analogs produced with genetic engineering possess antibacterial properties. In point of fact, one of these non-natural, biosynthetically produced darobactin (known as D22) suppressed A. baumannii in associated laboratory tests.
Progress Made in Darobactin Studies
In this current study however, a more extended group headed by Müller and Herrmann used the developed D22 compound to treat some of the most urgent bacterial infections in animals.
First, in zebrafish embryos, D22 treatment eradicated the infection by A. baumannii similar to ciprofloxacin, a broad-spectrum antibiotic used in complicated cultures.. Then the team conducted a series of efficacy and dosing trials with mice:
Best delivery method: From observations it was noted that use of D22 in injection form was more responsive than when given orally.
Efficacy against P. aeruginosa: Re-administration of D22 significantly suppressed the growth of P. aeruginosa in the infected mice thigh tissue and suppressed the infection but failed to eliminate the bacteria.